These data suggest that simvastatin treatment with mean duration 9.4 days is sufficient to deactivate PI3K/Akt/mTOR pathway and induce cancer cell apoptosis, while longer exposure with mean duration 21.5 days is required for deactivation of MAPK/ERK pathway in human breast cancer cells in vivo. The gene discussed is AKT1; the disease is breast carcinoma.